07.09.26 -- Applying Contamination Control By Design: A Practical Guide For CDMOs

Review essential considerations for AAV characterization and release from pre-clinical to late-phase pipelines. Address validation challenges to ensure the maturation of your analytics.

High-concentration protein formulations improve patient convenience but present viscosity risks. Discover innovative stabilization strategies to optimize quality and scalability for biologics.

This roundtable weaves together diverse, multifaceted perspectives on what it will take to create a sustainable path forward in rare disease drug development.

See how predictive in silico modeling accelerates biologics development by identifying stability and formulation risks early, enabling smarter candidate selection, reduced costs, and improved success rates.

Gain the foundational knowledge necessary to navigate complex CDMO partnerships. This guide helps developers manage expectations, mitigate supply chain risks, and accelerate project timelines.

Enzymatically produced DNA alternatives offer safer, faster vector scale-up. Explore how bacteria-free manufacturing methods reduce baseline costs while maximizing full capsid yields.

Fragmented data often delays outsourced gene therapy programs. Transition to an integrated operating model that unifies execution and risk data to enable rapid, data-driven decisions.